Abstract
Excretion of albumin in the urine is highly variable, ranging from nondetectable quantities to grams. Increased levels of albuminuria are highly prevalent in healthy individuals and even more so in hypertensive and diabetic populations. The variable excretion of albumin in the urine is related to the risk for the individual to develop cardiovascular disease (CVD): absence or very low levels of albuminuria is associated with low risk, whereas the risk continuously increases (with no thresholds) with increasing amount of urinary albumin. The predictive power of urinary albumin levels for CVD risk is independent of other CVD risk factors. Leakage of albumin appears to be associated with a defect in vascular permeability, most likely caused by a defect in the glycocalyx layer. This defect appears to be not only present in the kidneys but also in other vascular beds, providing a potential explanation as to why increased albuminuria not only predicts renal disease risk but also CVD risk. Treatments that lower albuminuria are associated with cardiovascular protection, as demonstrated in randomized controlled trials of diabetic as well as hypertensive patients. There is preliminary evidence that albuminuria lowering also protects healthy individuals with elevated albumin excretion rates. In conclusion, albuminuria appears to be a sensitive marker for the susceptibility of an individual to develop CVD. Lowering albuminuria appears to be associated with cardiovascular protection._It may therefore be a suitable target for early primary prevention using cardiovascular protective therapy regimens.
Keywords
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Levey AS, Eckardt KU, Tsukamoto Y et al (2005) Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 67:2089–2100
Zandi-Nejad K, Eddy AA, Glassock RJ et al (2004) Why is proteinuria an ominous biomarker of progressive kidney disease? Kidney Int Suppl 92:S76–89
Bakker SJ, Gansevoort RT, de Zeeuw D (2009) Albuminuria: what can we expect from the determination of nonimmunoreactive albumin? Curr Hypertens Rep 11:111–117.
Witte EC, Lambers Heerspink HJ, de Zeeuw D et al. (2009) First morning voids are more reliable than spot urine samples to assess microalbuminuria. J Am Soc Nephrol.20:436–443
Lambers Heerspink HJ, Brantsma AH, de Zeeuw D et al (2008) Albuminuria assessed from first-morning-void urine samples versus 24-hour urine collections as a predictor of cardiovascular morbidity and mortality. Am J Epidemiol 168:897–905
Brinkman JW, de Zeeuw D, Gansevoort RT (2007) Prolonged frozen storage of urine reduces the value of albuminuria for mortality prediction. Clin Chem. 53:153–154
Lambers Heerspink HJ, Nauta FL, Van der Zee C et al (2009) Alkalinization of urine samples preserves albumin concentrations during prolonged frozen storage in patients with diabetes mellitus. Diabet Med 26:556–559
de Zeeuw D, Parving HH, Henning RH (2006) Microalbuminuria as an early marker for cardiovascular disease. J Am Soc Nephrol 17:2100–2105
Brantsma AH, Bakker SJ, de Zeeuw D (2006) Urinary albumin excretion as a predictor of the development of hypertension in the general population. J Am Soc Nephrol 17:331–335
Brantsma AH, Bakker SJ, Hillege HL et al (2005) Urinary albumin excretion and its relation with C-reactive protein and the metabolic syndrome in the prediction of type 2 diabetes. Diabetes Care 28:2525–2530
Haraldsson B, Nystrom J, Deen WM (2008) Properties of the glomerular barrier and mechanisms of proteinuria. Physiol Rev 88:451–487
Satchell SC, Tooke JE (2008) What is the mechanism of microalbuminuria in diabetes: a role for the glomerular endothelium? Diabetologia 51(5):714–725
Mogensen CE (1984) Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med 310:356–360
Dinneen SF, Gerstein HC (1997) The association of microalbuminuria and mortality in noninsulin-dependent diabetes mellitus. A systematic overview of the literature. Arch Intern Med 157:1413–1418
Weir MR (2004) Microalbuminuria in type 2 diabetes: an important, overlooked cardiovascular risk factor. J Clin Hypertens 6:134–143
Yuyun MF, Dinneen SF, Edwards OM et al (2003) Absolute level and rate of change of albuminuria over 1 year independently predict mortality and cardiovascular events in patients with diabetic nephropathy. Diabet Med 20:277–282
Kannel WB, Stampfer MJ (1984) The prognostic significance of proteinuria: the Framingham Study. Am Heart J 108:1347–1352
Borch-Johnsen K, Feldt-Rasmussen B, Strandgaard S et al (1999) Urinary albumin excretion. An independent predictor of ischemic heart disease. Arterioscler Thromb Vasc Biol 19:1992–1997
Hillege HL, Fidler V, Diercks GFH et al (2002) Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in the general population. Circulation 106:1777–1782
Romundstad S, Holmen J, Kvenild K et al (2003) Microalbuminuria and all-cause mortality in 2,089 apparently healthy individuals: a 4.4-year follow-up study. The Nord-Trøndelag Health Study (HUNT), Norway. Am J Kidney Dis 42:466–473
Yuyun MF, Khaw KT Luben R et al (2004) Microalbuminuria independently predicts all-cause and cardiovascular mortality in a British population: The European Prospective Investigation into Cancer in Norfolk (EPIC-Norfolk) population study. Int J Epidemiol 33:189–198
Arnlov J, Evans JC, Meigs JB (2005) Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals: the Framingham Heart Study. Circulation 112:969–975
Olsen MH, Wachtell K, Ibsen H et al (2006) Reductions in albuminuria and in electrocardiographic left ventricular hypertrophy independently improve prognosis in hypertension: The LIFE Study. J Hypertension 24:775–781
Klausen K, Borch-Johnsen K, Jensen G et al (2004) Very low levels of microalbuminuria are associated with increased risk of coronary heart disease and death independently of renal function, hypertension, and diabetes. Circulation 110:32–35
Ratto E, Leoncini G, Viazzi F et al (2006) Microalbuminuria and cardiovascular risk assessment in primary hypertension: should threshold levels be revised? Am J Hypertens. 19:728–734
Bigazzi R, Bianchi S, Baldari D et al (1998) Microalbuminuria predicts cardiovascular events and renal insufficiency in patients with essential hypertension. J Hypertens 16:1325–1333
Jensen JS, Feldt-Rasmussen B, Strandgaard S (2000) Arterial hypertension, micro-albuminuria, and risk of ischemic heart disease. Hypertension 35:898–903
Wachtell K, Ibsen H, Olsen MH et al (2003) Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study. Ann Intern Med 139:901–906
Gerstein HC, Mann JF, Yi Q et al (2001) Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 286:421–426
Brantsma AH, Bakker SJ, Hillege HL et al (2008) Cardiovascular and renal outcome in subjects with K/DOQI stage 1–3 chronic kidney disease: the importance of urinary albumin excretion. Nephrol Dial Transplant. 2008 23:3851–3858
Ninomiya T, Perkovic V, de Galan BE et al (2009) Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J Am Soc Nephrol 20:1813–1821
Tonolo G, Ciccarese M, Brizzi P et al (1997). Reduction of albumin excretion rate in normotensive microalbuminuric type 2 diabetic patients during long-term simvastatin treatment. Diabetes Care 20:1891–1895
Nakamura T, Ushiyama C, Hirokawa K et al (2002) Effect of cerivastatin on urinary albumin excretion and plasma endothelin-1 concentrations in type 2 diabetes patients with microalbuminuria and dyslipidemia. Am J Nephrol 21:449–454
Gambaro G, Kinalska I, Oksa A et al (2002) Oral sulodexide reduces albuminuria in microalbuminuric and macroalbuminuric type 1 and type 2 diabetic patients: the Di.N.A.S. randomized trial. J Am Soc Nephrol 13:1615–1625
Agarwal R, Acharya M, Tian J et al (2005) Antiproteinuric effect of oral paricalcitol in chronic kidney disease. Kidney Int._68:2823–2828
Parving HH, Lehnert H, Brochner-Mortensen J et al (2001) The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345:870–878
Asselbergs FW, Diercks GFH, Hillege H et al (2004) Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation 110:2809–2816
de Zeeuw D, Remuzzi G, Parving HH et al (2004) Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation 110(8):921–927
de Jong PE, Curhan G (2006) Screening, monitoring and treatment of albuminuria — public health perspectives. J Am Soc Nephrol 17(8):2120–2126
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer-Verlag Italia
About this chapter
Cite this chapter
de Zeeuw, D., Lambers Heerspink, H.J. (2010). Increased Levels of Urinary Albumin: A Cardiovascular Risk Factor and a Target for Treatment. In: Berbari, A.E., Mancia, G. (eds) Cardiorenal Syndrome. Springer, Milano. https://doi.org/10.1007/978-88-470-1463-3_8
Download citation
DOI: https://doi.org/10.1007/978-88-470-1463-3_8
Publisher Name: Springer, Milano
Print ISBN: 978-88-470-1462-6
Online ISBN: 978-88-470-1463-3
eBook Packages: MedicineMedicine (R0)